KNSA Q4 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$202M+65.0% YoY

Gross Profit

$111M54.9% margin

Operating Income

$20M9.8% margin

Net Income

$14M7.0% margin

EPS (Diluted)

$0.18

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$53M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$764M

Total Liabilities

$196M

Stockholders' Equity

$568M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$123M	+65.0%
Gross Profit	$111M	$56M	+97.0%
Operating Income	$20M	-$19M	+202.4%
Net Income	$14M	-$9M	+259.8%

Revenue Segments

Product

$202M100%